The Mice Kept Eating Less and Put the Weight Back On Anyway. That Is the Interesting Part.

Here is the part worth reading twice. Those mice were still eating less. In some cases they ate slightly less than the comparison animals. The appetite effect was intact. The fat loss was not.

That separates two things usually treated as one. Eating less is not the same as losing fat, and in this experiment the drug needed the hunger neurons for the second even though it did not need them for the first. The implication is that these neurons help coordinate the metabolic side of the response, the mobilisation of stored fat, rather than merely governing the mouth.

Does this contradict the earlier work?

It contradicts a reasonable reading of it, and the reconciliation is the most useful thing in the story.

A 2025 mouse study found that fast acting GLP-1 drugs rapidly inhibited AgRP neurons, and that stronger inhibition went with a bigger drop in food intake. That is the opposite direction of travel.

Both can be true because they are measuring different clocks. The earlier work looked at the immediate appetite response, over hours. This one looked at prolonged treatment and at fat, over weeks. A circuit knocked down on day one and recruited by week six is not a contradiction, it is a sequence, and nobody had looked for the second phase because the first already explained the thing everyone was measuring.

What it does not show

That any of this happens in a person.

The work was done in mice, and in female mice specifically. Mouse energy metabolism is not human energy metabolism, the doses are not human doses, and the history of obesity research is substantially a history of mechanisms that were beautiful in rodents and absent in people. The authors say plainly that further research is needed before the finding can be translated.

It also does not change anything a patient should do this week. Nobody should read a mouse study as a reason to start, stop or alter a prescription, and the practical questions around these drugs remain the ones we have covered before: what happens to lean mass while the weight comes off, and what the evidence says about regain after stopping.

Why it matters anyway

Because it offers an answer to a question the field has been quietly embarrassed by for two years.

Older appetite suppressants blunted hunger perfectly well. They did not produce anything like this degree of durable fat loss, and the difference has never been properly explained by the appetite story alone. If GLP-1 drugs are also recruiting a metabolic response, and if that response is what makes the loss stick, then the gap between the old drugs and the new ones stops being mysterious.

It also complicates the shorthand that has attached itself to this class, which is that they simply make you eat less. If the mechanism is partly about what the body does with fat, the popular framing is not merely incomplete, it is pointed at the wrong organ. We set out the underlying pharmacology in how GLP-1 receptor agonists work, and the finding sits alongside a point we keep returning to, that the speed of weight loss is not evidence of anything.